THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Belluscura plc

("Belluscura" or the "Company" or "Group")

 Notice of AGM and Annual Report 2022

LONDON, U.K. AND PLANO, TX, U.S. (11 July 2023). Belluscura plc (AIM:BELL), announces that the Notice of Annual General Meeting ("AGM"), to be held on 14 September 2023, is being posted to shareholders and will shortly be available on the Company's website at: https://www.belluscura.com/corporate-governance/constitutional-documents.

The Annual Report and Accounts for the year ended 31 December 2022 is being posted along with the AGM notice and are available on the Company's website at: https://www.belluscura.com/financials/annual-and-interim-reports.

If you wish to submit a proxy vote for this meeting, please submit your vote online at www.signalshares.com. For your vote to be valid please ensure that it is received by no later than 12.00 p.m. on 12 September 2023. Alternatively, should you wish to vote via the CREST system, please see the instructions in the Notice of Meeting.

For further information please contact:

About Belluscura plc (www.belluscura.com)

Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.